{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:44:19Z","timestamp":1767134659329,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd000203.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T00:00:00Z","timestamp":1302652800000}}],"reference-count":110,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000203.pub3","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T17:19:01Z","timestamp":1302715141000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia"],"prefix":"10.1002","author":[{"given":"Samer","family":"Alabed","sequence":"first","affiliation":[{"name":"University of Oxford; Continuing Education; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Latifeh","sequence":"additional","affiliation":[{"name":"Al-Mowasat Hospital; Department of Psychiatry; Damascus University Damascus Syrian Arab Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam Aldeen","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Al-Mowasat Hospital; Department of Psychiatry; Damascus University Damascus Syrian Arab Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Rifai","sequence":"additional","affiliation":[{"name":"Damascus University; Faculty of Medicine; Damascus Syrian Arab Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,13]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0001|cit1","first-page":"111","article-title":"Baclofen in the treatment of tardive dyskinesia","volume":"42","author":"Ananth","year":"1987","journal-title":"Current Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD000203.pub3-BIB0002|cit2","first-page":"289","article-title":"Preliminary observations on the therapeutic action of progabide in tardive dyskinesia","volume":"2","author":"Burner","year":"1989","journal-title":"Brain Dysfunction"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1192\/bjp.150.4.542","article-title":"The effect of sodium valproate on tardive dyskinesia - revisited","volume":"150","author":"Fisk","year":"1987","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD000203.pub3-BIB0005|cit4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1176\/ajp.134.7.781","article-title":"The relationship between parkinsonism and tardive dyskinesia","volume":"134","author":"Gerlach","year":"1977","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0004|cit5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00431840","article-title":"Effect of baclofen on tardive dyskinesia","volume":"56","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.129.2.114","article-title":"Effect of sodium valproate on tardive dyskinesia","volume":"129","author":"Linnoila","year":"1976","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0007|cit7","first-page":"437","article-title":"Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies","volume":"24","author":"Nair","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1176\/ajp.135.12.1562","article-title":"Baclofen in the treatment of tardive dyskinesia","volume":"135","author":"Nair","year":"1978","journal-title":"American Journal of Psychiatry"},{"issue":"4 II","key":"10.1002\/14651858.CD000203.pub3-BIB0009|cit9","first-page":"A114","article-title":"Baclofen for tardive dyskinesia: a double-blind placebo-controlled trial","volume":"32","author":"Stewart","year":"1982","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002826-198212000-00004","article-title":"Baclofen in tardive dyskinesia patients maintained on neuroleptics","volume":"5","author":"Stewart","year":"1982","journal-title":"Clinical Neuropharmacology"},{"issue":"6","key":"10.1002\/14651858.CD000203.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/archpsyc.1987.01800180032006","article-title":"Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment","volume":"44","author":"Thaker","year":"1987","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0012|cit12","first-page":"483","article-title":"Sodium valproate in tardive dyskinesia","volume":"40","author":"Casey","year":"1979","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0013|cit13","first-page":"577","article-title":"Gamma-acetylenic GABA in tardive dyskinesia","volume":"24","author":"Casey","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD000203.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/archpsyc.1980.01780250062007","article-title":"Gamma-acetylenic GABA in tardive dyskinesia","volume":"37","author":"Casey","year":"1980","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0006-3223(92)90035-X","article-title":"GABA agonist induced changes in motor, oculomotor and attention measures correlate in schizophrenics with tardive dyskinesia","volume":"32","author":"Cassady","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0016|cit16","first-page":"236","article-title":"Pharmacologic relationship of anti saccade and dyskinesia in schizophrenic patients","volume":"29","author":"Cassady","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0017|cit17","first-page":"20","article-title":"Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia","volume":"14","author":"Chien","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0018|cit18","unstructured":"Chiu SS A placebo-controlled cross study of panax ginseng in augmentation of antipsychotics in 60 partially treatment responsive patients with schizophrenia http:\/\/www.clinicaltrials.gov 2006"},{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0019|cit19","first-page":"101","article-title":"Gamma-vinyl-GABA et dyskinesies tardives: une etude en simple insu contre placebo","volume":"142","author":"Danion","year":"1984","journal-title":"Annales Medico-Psychologiques Paris"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0020|cit20","unstructured":"Frangos E Athanasenas E Lioresal in the treatment of neuroleptic-induced tardive dyskinesia Proceedings of the12th CINP Congress; 1980 June 22-26; Goteborg, Sweden 1980"},{"issue":"3","key":"10.1002\/14651858.CD000203.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-0447.1983.tb00339.x","article-title":"Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind crossover study with placebo","volume":"67","author":"Friis","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1192\/bjp.133.1.82","article-title":"Sodium valproate and tardive dyskinesia","volume":"133","author":"Gibson","year":"1978","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00432517","article-title":"The treatment of tardive dyskinesia with baclofen","volume":"87","author":"Glazer","year":"1985","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-0447.1976.tb00122.x","article-title":"A double-blind trial of baclofen against placebo in the treatment of schizophrenia","volume":"54","author":"Gulmann","year":"1976","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0447.1976.tb00090.x","article-title":"Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia","volume":"54","author":"Korsgaard","year":"1976","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"9","key":"10.1002\/14651858.CD000203.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/archpsyc.1982.04290090021005","article-title":"The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist","volume":"39","author":"Korsgaard","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0027|cit27","unstructured":"Korsgaard S Casey D Gerlach J GABA agonist treatment of tardive dyskinesia Proceedings of the 13th Congress of Collegium Internationale Neuro-psychopharmacologicum; 1982 Jun 20-25; Jerusalem, Israel 1982"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0165-1781(83)90014-8","article-title":"Effect of gamma-vinyl GABA in tardive dyskinesia","volume":"8","author":"Korsgaard","year":"1983","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD000203.pub3-BIB0029|cit29","first-page":"371","article-title":"Therapeutic trial of gamma-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics","volume":"8","author":"Lambert","year":"1982","journal-title":"L'Encephale"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00177564","article-title":"Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia","volume":"96","author":"Monteleone","year":"1988","journal-title":"Psychopharmacology"},{"issue":"Suppl","key":"10.1002\/14651858.CD000203.pub3-BIB0031|cit31","first-page":"128","article-title":"Clinical activity of GABA agonists in neuroleptic and L-dopa-induced dyskinesia","volume":"2","author":"Morselli","year":"1985","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000203.pub3-BIB0032|cit32","first-page":"509","article-title":"Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in schizophrenic patients with tardive dyskinesia or drug-induced tremor","volume":"14","author":"Nagao","year":"1979","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-3223(85)90084-8","article-title":"A placebo-controlled trial of valproate in tardive dyskinesia","volume":"20","author":"Nasrallah","year":"1985","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0034|cit34","first-page":"56","article-title":"Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management","volume":"47","author":"Nasrallah","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0035|cit35","first-page":"423","article-title":"Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden","volume":"90","author":"Nordic Dyskinesia Study Group","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1600-0447.1990.tb06472.x","article-title":"Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide","volume":"81","author":"Raptis","year":"1990","journal-title":"Acta Psychatrica Scandinavica"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0037|cit37","unstructured":"Bathien N Sevestre P Rondot P Morselli PL Van Landeghem V The effect of progabide, a specific GABAergic agonist, on neuroleptic-induced tardive dyskinesia - a result of a pilot study Proceedings of the 13th Collegium Internationale Neuropsychopharmacologicum Congress; 1982 June 20-25; Jerusalem, Israel 1982"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0038|cit38","first-page":"361","article-title":"Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study","volume":"45","author":"Rondot","year":"1987","journal-title":"Advances in Neurology"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0039|cit39","unstructured":"Sikich L Williamson K Malekpour A Bashford RA Hooper S Sheitman B Lieberman JA Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico USA 1999"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0040|cit40","unstructured":"Sikich L Critical decisions in the treatment of adolescent and pediatric psychosis Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0041|cit41","unstructured":"Sikich L Horrigan JP Lieberman JA Barnhill LJ Sheitman BB Courvoisie HE Comparative use of olanzapine and risperidone in psychotic youth Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0042|cit42","unstructured":"Sikich L Critical decisions in the treatment of adolescent and pediatric psychosis Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0043|cit43","first-page":"16","article-title":"Baclofen in the treatment of tardive dyskinesia and schizophrenia","volume":"14","author":"Simpson","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD000203.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/0006-3223(85)90214-8","article-title":"Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders","volume":"20","author":"Stahl","year":"1985","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1176\/ajp.135.6.746","article-title":"Muscimol: GABA agonist therapy in schizophrenia","volume":"135","author":"Tamminga","year":"1978","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archpsyc.1979.01780050105013","article-title":"Improvement in tardive dyskinesia after muscimol therapy","volume":"36","author":"Tamminga","year":"1979","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000203.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3928\/0048-5713-19890601-08","article-title":"Gamma-aminobutyric-acid (GABA) pathways in tardive dyskinesia","volume":"19","author":"Nguyen","year":"1989","journal-title":"Psychiatric Annals"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(83)90075-2","article-title":"GABA agonist treatment improves tardive dyskinesia","volume":"2","author":"Tamminga","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0049|cit49","article-title":"Tardive dyskinesia: GABA agonist treatment","volume-title":"Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects","author":"Tamminga","year":"1994"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000408491","article-title":"GABA system: clinical research and treatment of tardive dyskinesia","volume":"21","author":"Thaker","year":"1983","journal-title":"Modern Problems in Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0051|cit51","first-page":"69","article-title":"Tardive dyskinesia: GABA agonist treatment","volume-title":"Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects","author":"Tamminga","year":"1984"},{"issue":"10","key":"10.1002\/14651858.CD000203.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM198109033051015","article-title":"Effects of gamma-vinyl GABA","volume":"305","author":"Tell","year":"1981","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0054|cit54","volume-title":"Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association","author":"American Psychiatric Association","year":"1992"},{"issue":"2-3","key":"10.1002\/14651858.CD000203.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2006.01.010","article-title":"Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis","volume":"83","author":"Bakker","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp.46.6.540","article-title":"A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals","volume":"46","author":"Barnes","year":"1983","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0057|cit57","article-title":"Tardive dyskinesia: risk factors, pathophysiology and treatment","volume-title":"Recent Advances in Clinical Psychiatry","volume":"6","author":"Barnes","year":"1988"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0058|cit58","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic Drugs and their Side-Effects","author":"Barnes","year":"1993"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.144.5.498","article-title":"Tardive dyskinesia: fluctuating patient or fluctuating rater","volume":"144","author":"Bergen","year":"1984","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000203.pub3-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0062|cit62","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0063|cit63","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-9964(98)00160-1","article-title":"Tardive dyskinesia and atypical antipsychotic drugs","volume":"35","author":"Casey","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000203.pub3-BIB0065|cit65","first-page":"5","article-title":"Tardive dyskinesia: pathophysiology and animal models","volume":"61","author":"Casey","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Chouinard G Chouinard VA Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes Psychotherapy and Psychosomatics 2008 69 77","DOI":"10.1159\/000112883"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0067|cit67","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD000203.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD000203.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0073|cit73","article-title":"The treatment of tardive dyskinesia","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Gardos","year":"1994"},{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000468206","article-title":"The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment","volume":"11","author":"Gerlach","year":"1976","journal-title":"International Pharmacopsychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000203.pub3-BIB0075|cit75","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the health survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"Journal of American Epidemiology"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic induced dyskinesia of regional changes in brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0078|cit78","volume-title":"ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health Publication No. 76-338","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0080|cit80","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2466\/pr0.1966.19.1.180","article-title":"NOSIE-30: A treatment-sensitive ward behavior scale","volume":"19","author":"Honigfeld","year":"1966","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0082|cit82","volume-title":"Understanding and Treating Tardive Dyskinesia","author":"Jeste","year":"1982"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD000203.pub3-BIB0083|cit83","first-page":"38S","article-title":"Pharmacological treatments of tardive dyskinesia in the 1980s","volume":"8","author":"Jeste","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000203.pub3-BIB0084|cit84","first-page":"27","article-title":"Tardive dyskinesia in older patients","volume":"61","author":"Jeste","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0085|cit85","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0447.1977.tb00174.x","article-title":"A standardized psychiatric assessment scale for rating chronic psychotic patients","volume":"55","author":"Krawiecka","year":"1977","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000203.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"Suppl 29","key":"10.1002\/14651858.CD000203.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/1451858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic induced tardive dyskinesia","author":"Lyra Da Silva","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00496058","article-title":"A rating scale for tardive dyskinesia","volume":"64","author":"Simpson","year":"1979","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206","article-title":"Diltiazem, nifedipine, nimodipine orverapamil for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000203.pub3-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub2","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.mp.4000249","article-title":"Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients","volume":"2","author":"Steen","year":"1997","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000203.pub3-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD000203.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Umbrich","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000203.pub3-BIB0107|cit107","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P Pinfold V Takriti Y The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007"},{"issue":"4","key":"10.1002\/14651858.CD000203.pub3-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Rathbone","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000203.pub3-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd000203.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD000203.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T16:55:19Z","timestamp":1628528119000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD000203.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,13]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000203.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,13]]}}}